{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=alprazolam",
    "query": {
      "intervention": "alprazolam"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 57,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=alprazolam&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T13:17:36.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04782388",
      "title": "Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants"
      ],
      "interventions": [
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-03-04",
      "completion_date": "2021-04-26",
      "has_results": false,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04782388"
    },
    {
      "nct_id": "NCT03286218",
      "title": "A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recreational Drug Use",
        "Prescription Drug Abuse (Not Dependent)"
      ],
      "interventions": [
        {
          "name": "Lasmiditan",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2017-09-15",
      "completion_date": "2017-11-20",
      "has_results": true,
      "last_update_posted_date": "2020-01-10",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286218"
    },
    {
      "nct_id": "NCT00004373",
      "title": "Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anxiety Disorder",
        "Panic Disorder"
      ],
      "interventions": [
        {
          "name": "alprazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 80,
      "start_date": "1997-03",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004373"
    },
    {
      "nct_id": "NCT07777965",
      "title": "Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Non-dependent, Recreational Sedative Users"
      ],
      "interventions": [
        {
          "name": "Alprazolam (Xanax)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin (Neurontin® (Registered Trademark))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2026-06-18",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07777965"
    },
    {
      "nct_id": "NCT03814733",
      "title": "Assessment of Effect of Rapastinel on Driving Performance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Driving Performance"
      ],
      "interventions": [
        {
          "name": "Rapastinel",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Rapastinel Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ketamine Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Naurex, Inc, an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 107,
      "start_date": "2018-11-05",
      "completion_date": "2019-04-03",
      "has_results": false,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "San Clemente, California",
      "locations": [
        {
          "city": "San Clemente",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814733"
    },
    {
      "nct_id": "NCT05626439",
      "title": "A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Staccato alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Oral alprazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-12-28",
      "completion_date": "2023-02-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05626439"
    },
    {
      "nct_id": "NCT00865761",
      "title": "A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Alprazolam 3 mg Extended Release Tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "XANAX XR® 3 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865761"
    },
    {
      "nct_id": "NCT00580190",
      "title": "Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "PF-00572778",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2007-09",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2009-09-14",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580190"
    },
    {
      "nct_id": "NCT06757140",
      "title": "Opioid Drug Interaction Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Drug Interactions",
        "Drug Kinetics"
      ],
      "interventions": [
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanna Babalonis, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-04-01",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06757140"
    },
    {
      "nct_id": "NCT01577706",
      "title": "Spectroscopic Imaging at 4T: A Drug Challenge Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "AOD Effects and Consequences"
      ],
      "interventions": [
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Dextroamphetamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mclean Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "21 Years to 45 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2013-06",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-09-03T13:17:36.503Z",
      "location_count": 1,
      "location_summary": "Belmont, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577706"
    }
  ]
}